Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 12, 2014
Previous Article Next Article

An azumamide C analogue without the zinc-binding functionality

Author affiliations

Abstract

Histone deacetylase (HDAC) inhibitors have attracted considerable attention due to their promise as therapeutic agents. Most HDAC inhibitors adhere to a general “cap-linker-Zn2+-binding group” architecture but recent studies have indicated that potent inhibition may be achieved without a Zn2+-coordinating moiety. Herein, we describe the synthesis of an azumamide analogue lacking its native Zn2+-binding group and evaluation of its inhibitory activity against recombinant human HDAC1–11. Furthermore, kinetic investigation of the inhibitory mechanism of both parent natural product and synthetic analogue against HDAC3-NCoR2 is reported as well as their activity against Burkitt's lymphoma cell proliferation.

Graphical abstract: An azumamide C analogue without the zinc-binding functionality

Back to tab navigation

Supplementary files

Article information


Submitted
13 Jun 2014
Accepted
11 Aug 2014
First published
12 Aug 2014

Med. Chem. Commun., 2014,5, 1849-1855
Article type
Concise Article

An azumamide C analogue without the zinc-binding functionality

J. S. Villadsen, B. Kitir, K. Wich, T. Friis, A. S. Madsen and C. A. Olsen, Med. Chem. Commun., 2014, 5, 1849
DOI: 10.1039/C4MD00252K

Search articles by author

Spotlight

Advertisements